Bupropion sustained release tablets, a new depression drug of Huahai pharmaceutical, was approved by FDA
-
Last Update: 2015-06-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Huahai Pharmaceutical (600521) announced in the evening of June 4 that the company had received a notice from the U.S Food and Drug Administration (FDA) recently The Anda of bupropion sustained-release tablets (specification: 100mg, 150mg, 200mg) declared by the company to FDA has been approved with approval number of 202304 The original research company of bupropion sustained release tablets is GlaxoSmithKline, which is mainly used to treat depression The acquisition of the preparation number indicates that the company has the qualification to sell the product in the U.S market According to IMS data, the total sales volume of bupropion sustained release tablets in the U.S market in 2014 was USD 183 million.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
